Year: 2005 Source: Canadian Medical Association Journal, v.173, no.12, (December 2005), p.1447 SIEC No: 20052118

As a non-stimulant, atomoxetine is a popular new treatment for attention-deficit hyperactivity disorder (ADHD). However, the US Food & Drug Administration & Health Canada recently warned of increased rates of suicidal ideation among children taking the drug in placebo-controlled trials. The meta-analysis that prompted the warnings reviewed 12 studies, 11 of ADHD & 1 of enuresis. Suicidal ideation is reported to have occurred in 0.37% of children given atomoxetine but none of 851 children given placebo. (LC) (3 refs)